Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Icosapent ethyl (Vascepa; Amarin) remains effective at reducing cardiovascular events in patients with elevated triglycerides but relatively well-controlled LDL cholesterol on a statin irrespective of ...

Elevated levels of lipoprotein(a) seem to be associated with greater subclinical interstitial myocardial fibrosis (IMF), increased myocardial scar prevalence, and left atrial remodeling by cardiac ...

FERNANDINA BEACH, Fla., November 4, 2025 – The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has launched the Lp(a) AW(a)RE ™ ...